Show simple item record

dc.contributor.authorMathai, VK
dc.contributor.authorAung, SY
dc.contributor.authorWong, V
dc.contributor.authorDunn, C
dc.contributor.authorShapiro, J
dc.contributor.authorJalali, A
dc.contributor.authorWong, R
dc.contributor.authorLee, M
dc.contributor.authorTie, J
dc.contributor.authorAnanda, S
dc.contributor.authorKosmider, S
dc.contributor.authorLim, SH
dc.contributor.authorCaird, S
dc.contributor.authorBurge, M
dc.contributor.authoret al.
dc.description.abstractIntroduction: The optimal management of isolated distant lymph node metastases (IDLNM) from a colorectal primary, is not clearly established. We aimed to analyze the outcomes of patients with IDLNM treated with systemic therapies plus locoregional therapy with curative intent versus systemic therapies with palliative intent. Materials & Methods: Clinical data were collected and reviewed from the Treatment of Recurrent and Advanced Colorectal Cancer registry, a prospective, comprehensive registry for metastatic colorectal cancer (mCRC) treated at multiple tertiary hospitals across Australia. Clinicopathological characteristics, treatment modalities and survival outcomes were analyzed in patients with IDLNM and compared to patients with disease at other sites. Results: Of 3408 mCRC patients diagnosed 2009 to 2020, with median follow-up of 38.0 months, 93 (2.7%) were found to have IDLNM. Compared to mCRC at other sites, patients with IDLNM were younger (mean age: 62.1 vs. 65.6 years, P = .02), more likely to have metachronous disease (57.0% vs. 38.9%, P < .01), be KRAS wild-type (74.6% vs. 53.9%, P< .01) and BRAF mutant (12.9% vs. 6.2%, P = .01). Amongst mCRC patients with IDLNM, 24 (25.8%) received treatment with curative intent and had a significantly better overall median survival than those treated with palliative intent (73.5 months vs. 23.2 months, P = .01). These 24 patients had an overall median survival similar (62.7 months, P = .82) to patients with isolated liver or lung metastases also treated with curative intent. Conclusion: Curative treatment strategies (radiotherapy or surgery), with or without systemic therapy, should be considered for mCRC patients with IDLNM where appropriate as assessed by the multidisciplinary team.
dc.publisherElsevier BV
dc.relation.ispartofjournalClinical Colorectal Cancer
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.keywordsColorectal cancer
dc.subject.keywordsLymph node
dc.titleTreatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMathai, VK; Aung, SY; Wong, V; Dunn, C; Shapiro, J; Jalali, A; Wong, R; Lee, M; Tie, J; Ananda, S; Kosmider, S; Lim, SH; Caird, S; Burge, M; et al., Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases, Clinical Colorectal Cancer, 2021
gro.description.notepublicThis publication has been entered as an advanced online version in Griffith Research Online.
gro.hasfulltextNo Full Text
gro.griffith.authorCaird, Susan

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record